Welcome to Hepatitis Delta Connect!
A dedicated program of the Hepatitis B Foundation to increase awareness about hepatitis delta - a serious virus that coinfects hepatitis B patients - and to promote screening and testing, and provide information and support for those affected.
Clinical Trial Finder - Find A Clinical Trial Near You!
Check Out Our Latest Podcast!
Bright and Evangeline sit down with Dan to talk about his experience with hepatitis Delta. We talk about his initial feelings surrounding the diagnosis, his treatment, how he got involved with the Hepatitis B Foundation, and his hope for the future of all people living with hepatitis B and Delta. Listen here today!
Check out our latest webinar!
Catch the recording of a recent webinar with Dr. Stephan Urban, head of the Translational Virology Unit at the Department of Infectious Diseases at Heidelberg University Hospital, and Project Coordinator in the German Center for Infection Research, TTU Hepatitis. Dr. Urban and his team developed the first commercially available and approved drug for hepatitis delta, known as bulevirtide, and he sheds light on the journey of this discovery and how this tremendous medical breakthrough was achieved. Watch today!
We would love to hear from you! Complete the survey to sign up! Please note: This survey link is specifically for those living with hepatitis delta, or those who are caretakers of people living with hepatitis delta.
Take our brief survey & sign up to receive updates on clinical trials, info about hepatitis delta monitoring, management & care + more! Sign up today! Please note: This survey link is specifically for healthcare providers caring for people living with hepatitis delta.
We've educated 13,000 people in 111 countries!
News & Updates
March 2023 Blog Post: Why Is Hepatitis Delta So Hard to Eliminate?
December 2022 Blog Post: What You Need to Know About the 2022 Liver Meeting and How it Relates to Hepatitis Delta
September 2022 Blog Post: What's the Difference? Herbal Remedies and Supplements vs. Western Medicine
July 2022 Blog Post: Results from Hepatitis Delta Clinical Trials Announced at 2022 International Liver Congress
May 2022 Blog Post: Roundtable Discussion Highlights Hepatitis Delta
View our webinar, "The Lived Experience of Hepatitis Delta" recording here.
01/21/2023: Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
01/11/2023: Identifying and Screening At-Risk Patients for Hepatitis Delta Virus: A Case Report
01/2023: D is for Diagnosis, Whom to Screen for hepatitis Delta virus
12/2022: Low Performance of Hepatitis Delta Virus Testing Among 2 National Cohorts of Chronic Hepatitis B Patients in the United States
12/8/2022: Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
11/12/2022: Bulevirtide maintains safety, efficacy in HDV-related compensated cirrhosis at 72 weeks
11/11/2022: Bulevirtide Improves Health-Related Quality of Life (Phase 3 Clinical Trial Presentation at AASLD)
11/04/2022: Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
10/27/2022: Gilead Receives Complete Response Letter from U.S. FDA for Bulevirtide for the Treatment of Adults with Hepatitis Delta Virus.
Gilead is discussing with the FDA to get bulevirtide approved in the US and bring the treatment to people living with HDV. Global advocates are still fighting for widespread access to effective hepatitis delta treatments.
10/27/2022: COVID-19 Impacts HDV Screening, Patient Outcomes
10/17/2022: Identification of a novel interaction site between the large hepatitis delta antigen and clathrin that regulates the assembly of genotype III hepatitis delta virus
Get Connected
